Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models
Melanoma models characterized by high levels of terminally exhausted CD8+T cells (TIM-3+) can be successfully treated with the anti-PD-1+LAG-3+TIM-3 combination. The observation that high TIM-3 expression in CD8+T cells is associated with ICI resistance suggests the potential utility of anti-TIM-3-based combinations as a second-line treatment strategy in patients with advanced melanoma.
Authors
- Y. Ann Chen (ORCID: https://orcid.org/0000-0003-1468-3490)
- Thi Tran (ORCID: https://orcid.org/0000-0003-4012-5898)
- Brian Ruffell (ORCID: https://orcid.org/0000-0002-3846-6872)
- Paulo C. Rodrı́guez (ORCID: https://orcid.org/0000-0001-7480-6566)
- Vincent C. Luca (ORCID: https://orcid.org/0000-0001-9427-5520)
- Keiran S.M. Smalley (ORCID: https://orcid.org/0000-0003-1089-9307)
- Sathya Neelature Sriramareddy (ORCID: https://orcid.org/0000-0001-9189-3956)
- Jiannong Li
- Manali S. Phadke (ORCID: https://orcid.org/0009-0009-4047-9304)
Institutions
- University of Utah (US)
- Moffitt Cancer Center (US)
- Utah Department of Health (US)
- University of Utah Health Care (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1136/jitc-2025-012011
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Florida Department of Health